Bone density and metabolism in subjects with microdeletion of chromosome 22q11 (del22q11).

INTRODUCTION Although hypoparathyroidism with hypocalcaemia is one of the most frequent clinical features of monoallelic microdeletion of chromosome 22q11 (22q11DS), bone mass and metabolism have not yet been assessed in these patients. DESIGN This study aimed to evaluate bone mass and metabolism in a cohort of patients, both children and adults, with 22q11DS. METHODS In twenty-eight patients with 22q11DS (median age 12.5, range 6.1-42.8 years), serum levels of ionised and total calcium, phosphate, parathyroid hormone (PTH), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, osteocalcin and bone-specific alkaline phosphatase (BSAP), and urinary deoxypyridinoline concentrations were evaluated. In these patients, bone mineral density (BMD) was evaluated by dual-energy X-ray absorptiometry (DXA) examination, and volumetric BMD (bone mineral apparent density (BMAD)) was calculated. The data obtained from paediatric and adult patients were compared with two age-, sex- and body size-matched healthy subject control groups. RESULTS Patients with 22q11DS showed a reduced BMAD Z-score compared with controls (P<0.001). These patients also had significantly lower ionised (P<0.001) and total calcium (P<0.05) levels as well as lower PTH levels (P<0.05), compared with the controls. In particular, children and young patients with 22q11DS had significantly lower serum osteocalcin levels (P<0.001), BSAP levels (P<0.001) and urinary deoxypyridinoline concentrations (P<0.001) than controls. These results were not confirmed in adults. Finally, patients with hypoparathyroidism and/or hypocalcaemia at the time of the study showed significantly lower ionised (P<0.001) and total calcium levels (P<0.001), PTH levels (P<0.05), BSAP levels (P<0.001), osteocalcin levels (P<0.001) and urinary deoxypyridinoline concentrations (P<0.001), compared with patients without hypoparathyroidism and/or hypocalcaemia. Nonetheless, the BMAD Z-score did not show substantial differences between these two groups. CONCLUSIONS Subjects with 22q11DS have a significant reduction in bone mass that appears to be more severe in adults who have already attained peak bone mass than in children who are still growing. Therefore, we suggest a close monitoring of bone mass and metabolism in 22q11DS patients.

[1]  J. Rotteveel,et al.  Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial. , 2009, The Journal of clinical endocrinology and metabolism.

[2]  J. Kaufman,et al.  Genome-wide linkage screen of bone mineral density (BMD) in European pedigrees ascertained through a male relative with low BMD values: evidence for quantitative trait loci on 17q21-23, 11q12-13, 13q12-14, and 22q11. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  A. Hokken-Koelega,et al.  Long‐term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small‐for‐gestational‐age: six‐year follow‐up of a randomized controlled GH trial , 2007, Clinical endocrinology.

[4]  F. Pedeutour,et al.  The spectrum of parathyroid gland dysfunction associated with the microdeletion 22q11. , 2006, European journal of endocrinology.

[5]  C. Fusch,et al.  Osteoporosis in Pediatric Patients Suffering From Chronic Inflammatory Bowel Disease With and Without Steroid Treatment , 2006, Journal of pediatric gastroenterology and nutrition.

[6]  F. Chiarelli,et al.  Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. , 2005, European journal of endocrinology.

[7]  R. Shprintzen,et al.  Defining the clinical spectrum of deletion 22q11.2. , 2005, The Journal of pediatrics.

[8]  D. Miao,et al.  Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. , 2004, Endocrinology.

[9]  E. Schoenau,et al.  The bone mass concept: problems in short stature. , 2004, European journal of endocrinology.

[10]  A. Fasth,et al.  Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden , 2004, Archives of Disease in Childhood.

[11]  D. Srivastava,et al.  Unraveling the genetic and developmental mysteries of 22q11 deletion syndrome. , 2003, Trends in molecular medicine.

[12]  J. Souberbielle,et al.  Parathyroid function and growth in 22q11.2 deletion syndrome. , 2003, The Journal of pediatrics.

[13]  S. Ljunghall,et al.  Bone Turnover Responses to Changed Physical Activity , 2003, Calcified Tissue International.

[14]  V. Gilsanz,et al.  Establishment of peak bone mass. , 2003, Endocrinology and metabolism clinics of North America.

[15]  A. F. Stewart,et al.  Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. , 2003, The Journal of clinical endocrinology and metabolism.

[16]  L. Bachrach.  Acquisition of optimal bone mass in childhood and adolescence , 2001, Trends in Endocrinology & Metabolism.

[17]  David J. Anderson,et al.  Genetic ablation of parathyroid glands reveals another source of parathyroid hormone , 2000, Nature.

[18]  O Johnell,et al.  Exercise during growth and bone mineral density and fractures in old age , 2000, The Lancet.

[19]  W. Greulich,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1999 .

[20]  A. Green,et al.  Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. , 1997, Journal of medical genetics.

[21]  E. Krenning,et al.  Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. , 1997, The Journal of clinical endocrinology and metabolism.

[22]  S. Gidding,et al.  Evolution of latent hypoparathyroidism in familial 22q11 deletion syndrome. , 1997, American journal of medical genetics.

[23]  H. Kröger,et al.  Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology. , 1995, Bone.

[24]  M. Garabédian,et al.  Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  E. Alhava,et al.  Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry. , 1992, Bone and mineral.

[26]  D. Carter,et al.  Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls. , 1991, The Journal of clinical endocrinology and metabolism.

[27]  J. Tanner,et al.  Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. , 1976, Archives of disease in childhood.

[28]  G. Saggese,et al.  Are adult patients with laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities. , 2004, The Journal of clinical endocrinology and metabolism.

[29]  S. Weinzimer.  Endocrine aspects of the 22q11.2 deletion syndrome , 2001, Genetics in Medicine.

[30]  E. Zackai,et al.  The Philadelphia story: the 22q11.2 deletion: report on 250 patients. , 1999, Genetic counseling.